247 related articles for article (PubMed ID: 11916232)
1. Future use of selective estrogen receptor modulators and aromatase inhibitors.
Howell A
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4402s-4410s; discussion 4411s-4412s. PubMed ID: 11916232
[TBL] [Abstract][Full Text] [Related]
2. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
3. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
4. Are aromatase inhibitors superior to antiestrogens?
Howell A; Buzdar A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors and breast cancer.
Miller WR
Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
[TBL] [Abstract][Full Text] [Related]
6. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
7. Prevention of hormone-related cancers: breast cancer.
Dunn BK; Wickerham DL; Ford LG
J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
[TBL] [Abstract][Full Text] [Related]
8. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
10. Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body.
Gadducci A; Cosio S; Genazzani AR
Curr Opin Investig Drugs; 2004 Oct; 5(10):1031-44. PubMed ID: 15535424
[TBL] [Abstract][Full Text] [Related]
11. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
Dunn BK; Ryan A
Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
[TBL] [Abstract][Full Text] [Related]
12. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF
Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
[TBL] [Abstract][Full Text] [Related]
13. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Jordan VC; Brodie AM
Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors: new endocrine treatment of breast cancer.
Brueggemeier RW
Semin Reprod Med; 2004 Feb; 22(1):31-43. PubMed ID: 15083379
[TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted endocrine therapies for breast cancer.
Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
[TBL] [Abstract][Full Text] [Related]
16. Optimal sequence of hormonotherapy in advanced breast cancer.
Bertelli G; Paridaens R
Curr Opin Oncol; 2006 Nov; 18(6):572-7. PubMed ID: 16988577
[TBL] [Abstract][Full Text] [Related]
17. [Selective estrogen receptor modulators (SERMs) in the practice].
Nagykálnai T
Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896
[TBL] [Abstract][Full Text] [Related]
18. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
Spicer J; Ellis P
Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
[TBL] [Abstract][Full Text] [Related]
19. SERMs: meeting the promise of multifunctional medicines.
Jordan VC
J Natl Cancer Inst; 2007 Mar; 99(5):350-6. PubMed ID: 17341726
[TBL] [Abstract][Full Text] [Related]
20. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]